Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.

Keywords

Tamoxifen, Medicine, Breast cancer, Stage (stratigraphy), Oncology

References

• Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.Pablo Cano — 1995
• Treatment of early-stage breast cancerÅsa Larsson — 1999
• National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.Patricia J. Eifel, Jan Axelson, Janitha Costa — 2001
• Applications of diffusion theory to cancer care in the United States, 1972-1981Elinor Schoenfeld — 1989
• Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.Aron Goldhirsch, John H. Glick, Richard D. Gelber — 2001
• Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data.Xianglin L. Du, James S. Goodwin — 2001
• The surveillance, epidemiology, and end results program: a national resource.Benjamin F. Hankey, Lynn A. G. Ries, B. K. Edwards — 1999
• A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.B. Fisher, Joseph Costantino, Carol Redmond — 1989
• UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.Richárd Pető, Jillian Boreham, Mike Clarke — 2000
• A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.B. Fisher, Carol Redmond, N V Dimitrov — 1989
• Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends.Holly L. Howe, Phyllis A. Wingo, M. J. Thun — 2001
• Adjuvant therapy for breast cancer: practice patterns of community physicians.Linda C. Harlan, Jeffrey S. Abrams, Joan L. Warren — 2002
• Utility of the SEER-Medicare Data to Identify Chemotherapy UseJoan L. Warren, Linda C Harlan, Angela Fahey — 2002
• Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996Xianglin L. Du, James S. Goodwin — 2001
• Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.V. Craig Jordan, Monica Morrow — 2003
• Understanding the genotoxicity of tamoxifen?David H. Phillips — 2001
• Discrepancy between Consensus Recommendations and Actual Community Use of Adjuvant Chemotherapy in Women with Breast CancerXianglin L. Du, Charles R. Key, Cynthia Osborne — 2003
• Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats.Peter Greaves, Rajiv Goonetilleke, Graham R. Nunn — 1993
• Tamoxifen therapy for breast cancer and endometrial cancer risk.Leslie Bernstein, Dennis Deapen, James R. Cerhan — 1999
• Adjuvant systemic therapy for early breast cancer.Craig Henderson — 1987

Cited by

• Adjuvant use of anastrozole in breast cancer.Graziela Cury, Mário Tomazello Filho — 2004
• Cancer mortality surveillance--United States, 1990-2000.Sherri L. Stewart, Jessica King, Trevor Thompson — 2004
• Cancer incidence, mortality and survival trends in Canada, 1970-2007.Linda Kachuri, P De, Larry F. Ellison — 2013
• Costs of adjuvant breast cancer treatments.Nina Oestreicher — 2009
• USE OF ORAL CHEMOTHERAPEUTIC MEDICATIONS IN NON-TRADITIONAL AMBULATORY SETTINGSSameer Arora — 2009
• Timely detection of cancer relapse : routine follow-up in patients treated for ovarian and breast cancerSandra M. E. Geurts — 2013
• Mammography Rates for Breast Cancer Screening: A Comparison of First Nations Women and All Other Women Living in Manitoba, Canada, 1999–2008Alain Demers, Kathleen Decker, Erich V. Kliewer — 2015
• Optimierung der Therapie des metastasierten Mammakarzinoms unter besonderer Berücksichtigung des Pi3K/Akt/mTOR-SignaltransduktionswegsJan Eucker — 2013
• Concordance of hospital-based cancer registry data with a clinicians' database for breast cancer.Mingji Zhang, Takahiro Higashi, Hiroshi Nishimoto — 2012
• Incidence and Mortality in Breast Cancer: Are We Doing Better?Lieveke Ameye, Michel Moreau, Marianne Paesmans — 2007
• Survival Outcomes and Pathologic Features Among Breast Cancer Patients Who Have Developed a Contralateral Breast CancerErik Liederbach, Chi‐Hsiung Wang, Waseem Lutfi — 2015
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.2005
• Xenobiotic transporter expression in breast cancer patients treated with neoadjuvant systemic therapy: implications for therapyBaek Kim — 2014
• Sulfotransferase 1A1 (SULT1A1) gene expression is regulated by members of the NFI transcription factors in human breast cancer cellsAiwei Yao‐Borengasser, Lora J. Rogers, Vineetha Koroth Edavana — 2014
• Selective Application of Axillary Node Dissection in Elderly Women with Early Breast CancerDalal Aziz, Sandra Gardner, Kathleen I. Pritchard — 2007
• Tamoxifen: an emerging preventive.Jan Schwartz — 2004
• Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews.Xianglin L. Du, Charles R. Key, Lois Dickie — 2006
• Effects of Estrogen Receptor Expression and Histopathology on Annual Hazard Rates of Death from Breast CancerWilliam F. Anderson, Bingshu E. Chen, Ismail Jatoi — 2006
• Effect of screening and adjuvant therapy on mortality from breast cancer.Donald A. Berry, Kathleen A. Cronin, Sylvia K. Plevritis — 2006
• Metachronous skeletal osteosarcoma after therapy.Norman Jaffe — 2004

Related papers

• Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer.A. Rubagotti, Allison Perrotta, Claudia Casella — 1996
• Long-Term Tamoxifen Treatment for Breast CancerV. Craig Jordan — 1994
• Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patientsSusan Nowell, Jiyoung Ahn, James M. Rae — 2005
• Predicting Prognosis and Tamoxifen Response in Breast Cancer. With a special focus on contralateral breast cancer.Sara Alkner — 2012
• The Effects of Tamoxifen and Chemotherapy after Surgery on the Recurrence and Survival of Breast Cancer Patients with Positive Hormone Receptor: A Meta-AnalysisTrisakti Halimah Delimasari, Didik Tamtomo, Bhisma Murti — 2019
• CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.Rikje Ruiter, Monique J. Bijl, Ron HN van Schaik — 2010
• Gene Expression Signatures That Predict Outcome of Tamoxifen-Treated Estrogen Receptor-Positive, High-Risk, Primary Breast Cancer Patients: A DBCG StudyMaria Lyng, Anne‐Vibeke Lænkholm, Qihua Tan — 2013
• Effect of PR expression on sensitivity of chemotherapy with TC regimen in locally advanced breast cancerXiaojiao Chen — 2009
• Neoadjuvant Chemotherapy for Breast Cancer and Biological Markers Predicting Curative EffectRen Zhuan-qi — 2010